M. Alexander Otto, PA, MMS August 26, 2022 The study was published on researchsquare.com as a preprint and has not yet been peer reviewed. Key Takeaway Combining autologous stem cell transplantation with anti-CD30 chimeric antigen receptor T-cell therapy is a highly effective treatment for relapsed/refractory CD30+ lymphoma, even for patients with PET-positive and chemorefractory disease. Why This Matters...